CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2025年8月3日～2025年8月9日の間に収集した論文情報を追加しました。

  1. Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data.

  セマグルタイドの抑うつ障害

  対象DB：FAERS,VigiBase

  2. Sex differences in drug-induced osteoporosis: a pharmacovigilance study based on the FAERS database.

  薬剤性骨粗鬆症の性差リスク

  対象DB：CVAR,FAERS

  3. Pharmacovigilance of obeticholic acid: An analysis of the Food and Drug Administration Adverse Event Reporting System database.

  オベチコール酸の有害事象解析

  対象DB：FAERS

  4. Evaluation and study of adverse reactions to imiglucerase based on the FAERS database.

  イミグルセラーゼの安全性評価

  対象DB：FAERS

  5. Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database.

  小児IBD治療薬IFXとADAの安全性

  対象DB：FAERS

  6. A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system.

  ボルチオキセチンの安全性評価

  対象DB：FAERS

  7. Safety assessment of Osilodrostat: The adverse event analysis based on FAERS database by means of disproportionality analysis.

  オシロドロスタットの有害事象解析

  対象DB：FAERS

  8. Real-world pharmacovigilance assessment of hepatotoxicity risk with HER2-Targeted drugs using FAERS database analysis.

  HER2標的治療薬の肝毒性リスク

  対象DB：FAERS

  9. Torsade de Pointes and QT Prolongation Among Antifungal Triazoles: A Real-World, Retrospective, Observational, Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.

  抗真菌トリアゾールとTdP/QT延長

  対象DB：FAERS

  10. A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database.

  セルトリズマブ ペゴルの安全性評価

  対象DB：FAERS

  11. Beyond the Prostate: A Visionary Study on Ocular Impacts of Benign Prostatic Hyperplasia Drugs.

  BPH薬と眼有害事象の関連

  対象DB：FAERS

  12. Infective pneumonia following the use of tumor necrosis factor-alpha inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.

  TNFα阻害剤と感染性肺炎の関連

  対象DB：FAERS

  13. Cardiac Adverse Events Associated With Elotuzumab: A Disproportionality Analysis Using FDA Adverse Event Reporting System.

  エロツズマブ関連心臓有害事象：FAERS不均衡性解析

  対象DB：FAERS

  14. Anaphylaxis to Penicillin: Harvesting Insights from the Food and Drug Administration's Adverse Event Reporting System.

  ペニシリン誘発アナフィラキシーの疫学

  対象DB：FAERS

  15. Safety monitoring of Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System (VAERS), 2023-2024, United States.

  RSV母子ワクチン接種後の安全性評価

  対象DB：FAERS,VAERS

  16. Association between antibody-dependent cellular cytotoxicity activity of antitumor antibodies and infusion reactions: a pharmacovigilance analysis using the Japanese adverse drug event report database.

  ADCC活性と抗腫瘍抗体の輸注反応リスクを解析

  対象DB：JADER

  17. Model-informed drug repurposing of proton pump inhibitors for the prevention of oxaliplatin induced peripheral neuropathy: A real-world data analysis and pharmacometrics approach.

  オメプラゾールのOIPN抑制効果を実証データで評価

  対象DB：JADER

  18. Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events.

  抗VEGF薬の心血管・脳血管リスクをJADERで分析

  対象DB：JADER

  19. Pharmacovigilance: Overview of Italian and European regulations, tools, and perspectives.

  イタリアのPVシステム、進展と課題を評価

  対象DB：EudraVigilance

  20. Management of inpatient chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell malignancies: an analysis using the Japanese Diagnosis Procedure Combination database.

  CAR-T療法後の周術期管理実態をRWEで解明

  対象DB：DPC

  21. Evaluating the Potential of Prevalent New User Design as an Alternative When New User Design is Impractical.

  既存薬歴考慮の新規ユーザー設計がリスク評価に有効

  対象DB：JMDC

  22. Developing Data Analysis Skills for Local Medical Administration Personnel Using the National Database and Business Intelligence System (Tableau).

  岡山県がNDB活用研修を成功裡に実施、資源公開

  対象DB：NDB

  23. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society.

  SGLT2阻害剤は高齢HF患者の予後改善に有効

  対象DB：NDB

  24. Trend in prescription and treatment retention of molecular-targeted drugs in 121,131 Japanese patients with rheumatoid arthritis: A population-based real-world study.

  RA治療薬の維持率は非TNF阻害薬が高い

  対象DB：NDB

  25. Regulatory-required post-marketing database studies in Japan could be leveraged to assess important potential risks as well as identified risks.

  日本のPMDSは安全性重視のコホート研究が主流?

  対象DB：MDV

  26. First trimester antidepressant use and miscarriage: a comprehensive analysis in the Clinical Practice Research Datalink GOLD.

  妊娠初期の抗うつ薬使用は流産リスク僅かに増加

  対象DB：CPRD

  27. Examining variations in the prevalence of hazardous opioid prescribing across general practices in England: a cross-sectional study.

  危険なオピオイド処方は貧困層で多く、地域差が存在

  対象DB：CPRD

  28. The incidence and mortality of connective tissue diseases: a population-level cohort study in England from 2012 to 2023.

  CTDの発生率は変動し、IIMとSScで死亡率が高い

  対象DB：CPRD

  29. Social determinants of heat-related mortality in England: a time-stratified case-crossover study using primary care records.

  高齢者や女性、少数民族、貧困層が暑さで死亡リスク増

  対象DB：CPRD

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み